Journal article
LBA89 A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21
Authors
Chi KN; Saad F; Ding K; Bauman G; Emmenegger U; Hotte SJ; Pouliot F; Lee J; Beauregard J-M; Nappi L
Journal
Annals of Oncology, Vol. 36, , pp. s1745–s1746
Publisher
Elsevier
Publication Date
September 1, 2025
DOI
10.1016/j.annonc.2025.09.105
ISSN
0923-7534